🔬 100K+ researchers trust BodyHackGuide — Join r/BodyHackGuide

Immune & InflammationPreclinical

LL-37 Dosage Guide: Protocols, Calculator & Safety

Everything you need to know about LL-37 dosing — protocols, safety, and where to buy.

Dosage Calculator

Calculate exact dosing for LL-37.

Dosing Protocols

Beginner

Context: LL-37 off-label use is more nuanced than many peptides — the therapeutic window is narrower, the side-effect profile is less benign, and the indications are specific rather than general wellness. This protocol is for users who have identified a specific clinical reason for LL-37 use and have ideally consulted with an integrative clinician.

Pre-Use Optimization (Before First Dose):

Verify vitamin D status: 25-OH-D should be >40 ng/mL. If deficient, optimize for 4-8 weeks before adding exogenous LL-37 — endogenous upregulation may resolve the issue without exogenous peptide.
Rule out contraindications: personal or family history of psoriasis, rosacea, lupus, or mast cell activation syndrome. These are strong relative contraindications.
Document baseline: CBC with differential, comprehensive metabolic panel, CRP, ferritin, vitamin D, relevant infection markers (if chronic infection is the target)
Source quality peptide: LL-37 synthesis is more complex than many peptides; product quality matters more. Use vendors with published HPLC certificates showing >95% purity.

Reconstitution: A 5 mg LL-37 vial reconstituted with 2 mL bacteriostatic water yields 2.5 mg/mL. On a U-100 insulin syringe: 1 unit (0.01 mL) = 25 μg, 4 units = 100 μg, 8 units = 200 μg, 20 units = 500 μg.

Initial Trial Dose (Test Tolerance):

Day 1: 100 μg subcutaneous (small test dose)
Wait 48-72 hours to assess tolerance — watch for excessive injection site inflammation, systemic symptoms, psoriasis/rosacea flare, any concerning reaction
If well tolerated, proceed

Standard Protocol A: Chronic Infection Support

Week 1: 200 μg subcutaneous 3x weekly (M/W/F)
Weeks 2-6: 500 μg subcutaneous 3x weekly
Weeks 7-8: taper to 250 μg 2x weekly
Break: 4 weeks off
Reassess clinical status; repeat cycle if benefit documented, discontinue if no benefit

Standard Protocol B: Wound Healing Adjunct (Topical) For topical application on chronic wounds or infected skin:

Compound with appropriate topical vehicle (clinician/pharmacy needed)
Apply per clinician direction (typically once daily under dressing)
Reserved for infected wounds not responding to standard care

Standard Protocol C: Systemic Antimicrobial Support For suspected systemic infection unresponsive to conventional therapy alone:

250-500 μg subcutaneous daily for 2-4 weeks
Combine with relevant conventional antimicrobials per clinician
Monitor response with clinical and laboratory markers

What to Expect:

Injection site reactions are more prominent than with benign peptides — expect mild-to-moderate redness, soreness, occasional itching lasting 12-48 hours
Systemic effects vary: some users note mild flu-like symptoms with initial doses, which usually diminish with continued dosing
Clinical benefits (if any) emerge over 2-6 weeks
Lab markers: inflammatory markers (CRP, ESR) may transiently rise in the first weeks of dosing reflecting immune activation, then stabilize or decline

Safety Monitoring:

Watch for unusual skin reactions (plaque-like redness, scaling) that could indicate psoriasis induction
Monitor for rosacea-like facial flushing/inflammation
Check basic renal function (BUN, creatinine) at baseline and at 4-6 weeks for longer courses
Any concerning symptoms warrant stopping and clinician consultation

When to Stop:

Any skin finding suggesting new-onset psoriasis, rosacea, or autoimmune dermatosis
Severe injection site reactions
Systemic symptoms beyond mild and transient flu-like signs
No clinical benefit after adequate trial (6-8 weeks)
Any significant change in lab parameters

Safety Considerations for Beginners:

Never start at high doses (500+ μg) without initial tolerance testing
Never use for vague "wellness" indications without specific clinical rationale
Do not combine with multiple other peptides initially — layer in LL-37 alone first to assess individual response
Work with an integrative clinician whenever possible, particularly for chronic infection use cases

Standard

For users who have completed a beginner cycle without adverse effects and have a documented specific indication.

Extended Protocols for Chronic Infection Syndromes:

Chronic Lyme, chronic viral reactivation, mold-related illness, and similar syndromes often require longer treatment than acute infection. Intermediate protocols:

Induction phase: 500 μg daily for 4-6 weeks
Maintenance phase: 500 μg 3x weekly for 8-16 additional weeks
Break: 4-8 weeks
Reassessment: clinical response, lab markers, quality of life

These longer protocols increase cumulative exposure and therefore both potential benefit and side-effect risk. Regular lab monitoring becomes more important.

Dose Range Exploration:

Some users find 250 μg effective; others require 500-750 μg
Dose escalation should be gradual (step up by 100-250 μg every 4-7 days) to assess tolerance at each level
Doses above 1 mg per injection are not supported by evidence and add risk without clear benefit

Combination Optimization:

Chronic Lyme Integrative Protocol:

LL-37 500 μg SC 3x weekly
Thymosin-Alpha-1 1.6 mg SC 2x weekly
Conventional antibiotics per clinician
Herbal antimicrobials (cryptolepis, knotweed, etc.)
Biofilm disruptors (NAC, monolaurin)
Low-dose naltrexone for inflammation modulation
Mitochondrial support (CoQ10, alpha-lipoic acid, MOTS-c)
Vitamin D >50 ng/mL, zinc adequacy

Chronic Infected Wound Adjunct Protocol:

Topical LL-37 per compounded formulation
Systemic LL-37 250-500 μg daily
BPC-157 250 μg BID for tissue repair
TB-500 2 mg 2x weekly
Conventional wound care and debridement as indicated

Post-Viral Syndrome (Long COVID, Post-EBV, etc.) Protocol:

LL-37 250-500 μg SC 3x weekly (cautious use given inflammatory potential)
Thymosin-Alpha-1 1.6 mg 2x weekly
Appropriate antivirals per clinician
Mitochondrial and metabolic support
Graded exercise and pacing as tolerated

Tracking Response:

Symptom diary with structured scales
Inflammatory markers (CRP, ESR) every 4-6 weeks
CBC with differential every 4-6 weeks
Kidney function every 4-6 weeks with longer protocols
Relevant infection markers (PCRs, antibody titers) for specific infections
Quality of life and functional measures

Non-Response Troubleshooting:

Verify product quality — LL-37 activity is sensitive to synthesis quality
Check vitamin D status — suboptimal levels reduce LL-37 efficacy
Assess adherence and proper injection technique
Consider whether indication matches LL-37 mechanism (some infections are not membrane-susceptible)
Consider if symptoms reflect dysregulation that requires immune modulation rather than antimicrobial approach

Cycle Considerations:

Breaks of 4-8 weeks between extended courses reasonable
Continuous daily dosing >16 weeks is uncharacterized
Long-term intermittent use (e.g., 8-week cycles 2-3 times yearly) is the most common pattern for chronic indications

Still Recommended:

Work with Lyme-literate, integrative, or functional medicine clinician for chronic infection contexts
Document baseline and follow-up with objective measures
Don't rely on LL-37 alone for serious infection — combine with appropriate primary therapy

Advanced

For experienced users with complex clinical contexts, ideally with integrative clinician oversight.

Scenario 1: Refractory Chronic Lyme / Tick-Borne Complex

Users with well-documented chronic Lyme or co-infection who have failed multiple conventional rounds:

Extended LL-37 protocols (3-6 months of cyclical dosing)
Coordinate with Lyme-literate infectious disease specialist
Comprehensive approach: LL-37 + Tα1 + targeted antibiotics + herbal antimicrobials + biofilm disruptors + immune modulation + mitochondrial support
Regular monitoring for response and adverse events
Realistic expectations: chronic Lyme responds slowly; LL-37 is adjunctive, not curative

Scenario 2: Post-Viral / Long COVID Complex With Inflammatory Dysregulation

For users with documented post-viral immune dysfunction:

LL-37 used cautiously given the inflammatory-potential concern
Consider 250 μg doses rather than 500 μg
Pair with immune-modulating rather than purely immune-activating approaches
Monitor carefully for worsening rather than improvement
Some users may paradoxically worsen with LL-37 — be prepared to stop

Scenario 3: Chronic Infected Wounds (Diabetic Foot Ulcers, Venous Stasis Ulcers)

Where LL-37 has the most clinical evidence (topical applications):

Topical compounded LL-37 per wound-care specialist
Systemic support 250-500 μg SC 3x weekly
Combine with optimized glycemic control, compression therapy, debridement, infection management
Wound care specialist oversight is important

Scenario 4: Refractory Biofilm Infections

Chronic sinusitis, prosthetic joint infections, chronic bacterial vaginosis, some dental infections:

LL-37's anti-biofilm activity is the specific rationale
Combine with conventional antibiotic strategy per specialist
Targeted topical application where possible (sinus irrigation, local compounding)
Systemic LL-37 where topical not feasible

Scenario 5: Mold / Mycotoxin-Related Illness

Controversial but common peptide-community use:

LL-37 has some antifungal activity
Evidence base for chronic mold illness is thin
Focus should be on exposure elimination and environmental remediation first
Peptide support (LL-37, Tα1, BPC-157) secondary to exposure mitigation

Advanced Dosing Strategies:

Pulse dosing: short high-intensity courses (500-750 μg daily for 2-4 weeks) separated by longer recovery periods, attempting maximum antimicrobial effect while minimizing cumulative exposure
Targeted topical with limited systemic: localized disease gets topical LL-37 (compounded); minimal systemic exposure limits side-effect risk
Alternating with other antimicrobial peptides: rotating between LL-37 and other approaches may reduce resistance or tolerance development

Advanced Cautions:

Long-term LL-37 use may alter skin microbiome and potentially trigger skin conditions in susceptible individuals
Chronic high-dose use may theoretically produce unrecognized renal effects; monitor kidney function
Adverse effects can be delayed or cumulative; not all side effects appear with first doses
Combining multiple antimicrobial peptides (LL-37, other defensins) is uncharacterized and not recommended

When to Discontinue:

Any new skin condition consistent with psoriasis, rosacea, or autoimmune dermatosis
Progressive renal function decline
Persistent inflammatory symptoms without benefit
Lack of clinical improvement after adequate trial
Cost-benefit consideration — LL-37 is expensive for long-term use
Pregnancy or attempted conception

Medical Supervision:

Advanced LL-37 use benefits significantly from integrative clinician oversight. Solo use for complex chronic illness is not recommended given the specificity of appropriate indications and the risk of adverse effects in susceptible populations.

Commonly Stacked With

LL-37 is most often stacked in chronic infection and inflammation contexts, usually with careful attention to indication rather than general wellness combinations.

LL-37 with Thymosin-Alpha-1: Complementary immune strategy: Tα1 modulates adaptive immunity (T-cell, dendritic cell function) while LL-37 provides direct antimicrobial activity and shapes innate immune response. This combination is used in chronic infection contexts (chronic Lyme, post-viral syndromes) to address both the pathogen directly (LL-37) and the host immune dysregulation that often accompanies chronic infection (Tα1). No known pharmacological interaction. Typical schedules: LL-37 daily or every-other-day alongside Tα1 twice weekly.

LL-37 with BPC-157 and TB-500: BPC-157 and TB-500 provide tissue repair and vascular protection while LL-37 provides antimicrobial effect. Useful in chronic wound healing contexts, post-infection recovery, and some GI-related infection scenarios. No known pharmacological interaction, but the combined injection burden can be substantial.

LL-37 with Conventional Antibiotics: Potential synergy — LL-37 has in vitro synergy with several conventional antibiotics, particularly against biofilm-embedded organisms. In practice, stacking LL-37 with prescribed antibiotics for biofilm-mediated chronic infections (some dental infections, prosthetic joint infections, chronic sinusitis) is used in peptide-community protocols but lacks rigorous supporting evidence.

LL-37 with Vitamin D: Vitamin D upregulates endogenous LL-37 production. Ensuring vitamin D sufficiency (25-OH-D > 40 ng/mL) is a baseline recommendation for anyone using LL-37 because it supports endogenous peptide levels. Vitamin D alone (without exogenous LL-37) is the first-line intervention for optimizing cathelicidin-mediated immunity.

LL-37 with Zinc, Lactoferrin, and Other Antimicrobial Factors: Non-interacting; complementary strategies for innate immune support. Commonly combined in integrative infection protocols.

LL-37 with MOTS-c and Mitochondrial Peptides: No known interaction. Different pathways — LL-37 antimicrobial, MOTS-c metabolic.

LL-37 with Oxytocin, PT-141, or Kisspeptin-10: Unrelated pharmacology; no interaction concerns.

LL-37 with Growth-Hormone-Axis Peptides: No direct interaction. Can be combined in comprehensive recovery/wellness regimens.

AVOID Combining LL-37 With:

Psoriasis biologics (ustekinumab, secukinumab, ixekizumab, guselkumab) where psoriasis is already diagnosed — psoriasis is partly LL-37-driven; adding LL-37 in a psoriasis patient is counterproductive and pharmacologically opposed to the therapy.
Active systemic inflammation drug regimens for lupus, rheumatoid arthritis, IBD — theoretical flare risk.
High-dose corticosteroids for autoimmunity — may not add benefit and may confuse treatment-response assessment.

Chronic Lyme / Tick-Borne Illness Protocols (Clinician-Guided):

LL-37 is often part of complex protocols that may include:

Conventional antibiotics (doxycycline, amoxicillin, azithromycin, ceftriaxone)
Herbal antimicrobials (cryptolepis, Japanese knotweed, artemisinin)
Biofilm disruptors (N-acetylcysteine, monolaurin, certain enzymes)
Immune support (Tα1, low-dose naltrexone)
Mitochondrial support (CoQ10, MOTS-c, alpha-lipoic acid)

These protocols are individualized and should be directed by Lyme-literate clinicians aware of the specific infection context.

Chronic Gut Infection Contexts:

LL-37 has been explored for chronic GI infections (SIBO, candida overgrowth, Blastocystis, various pathogens). Often combined with:

Oral antimicrobial agents (berberine, oregano oil, allicin)
Oral LL-37 (less effective than injection but used topically in GI)
Biofilm disruptors
Post-treatment probiotic protocols

Timing Considerations:

LL-37 injection can produce transient local or systemic inflammation; don't schedule dose immediately before important activities requiring peak function
Morning dosing typical to avoid sleep disruption from any inflammatory response
Multiple peptide injections in same session: use different injection sites to avoid confounding local reactions

Non-Peptide Foundation for LL-37 Optimization:

Vitamin D 25-OH-D > 40 ng/mL (often 50-60 for active users)
Adequate zinc (usually requires supplementation to reach RDA)
Adequate protein intake for endogenous peptide synthesis
Sleep and circadian optimization
Stress management (chronic cortisol reduces LL-37)

Side Effects & Safety

LL-37 has a less benign side-effect profile than many peptides covered in this guide, reflecting its mechanistic potency and narrow therapeutic window. **Common (injection site):** - **Injection site irritation** — more pronounced than with most peptides. Redness, soreness, occasional mild inflammation that can persist 24-48 hours - **Transient local warmth or burning sensation** — reflects local mast cell activation and chemotaxis - **Small bruise or induration at injection site** — common - **Histamine-like reactions at injection site** — mild local itch or urticarial wheal **Systemic Inflammatory:** - **Transient low-grade fever or chills** — particularly with early doses or higher doses; reflects immune activation - **Mild fatigue or malaise** — first 24 hours after injection in some users - **Transient joint aches** — reflects cytokine-mediated effects - **Mild flushing** — uncommon but reported **Potentially Serious Concerns:** - **Worsening of psoriasis or rosacea** — LL-37 is implicated in the pathogenesis of these conditions. Users with personal or family history of psoriasis or rosacea may experience disease flare. This is a significant concern specific to LL-37 not shared by most other peptides. - **Unmasking or triggering of autoimmune skin disease** — similar mechanism; rare but documented. - **Hemolysis at high doses or with rapid injection** — LL-37's membrane-disrupting activity can affect red blood cells at sufficient concentrations. - **Cytokine release in susceptible individuals** — particularly in users with existing chronic inflammation or mast cell activation syndrome. **Autoimmune / Inflammatory Disease Considerations:** This is the most important unique concern for LL-37: - **Lupus:** LL-37 complexed with self-DNA contributes to lupus pathogenesis in some models; avoid in active lupus. - **Psoriasis / psoriatic arthritis:** LL-37 is part of psoriasis disease mechanism; avoid in active psoriasis. - **Rosacea:** dysregulated cathelicidin processing drives rosacea; avoid in active rosacea. - **Mast cell activation syndrome:** LL-37 activates mast cells; may worsen MCAS symptoms. **Nephrotoxicity Concerns:** Preclinical data suggest renal filtration and accumulation of cationic peptides can produce tubular toxicity at high doses. Rarely documented in published human use at typical doses but remains a theoretical concern for prolonged high-dose use. **Infection-Related Concerns:** Paradoxically, LL-37 can promote certain infections: - **Group A streptococcus** — some strains have evolved resistance mechanisms that use LL-37 to enhance virulence - **Staphylococcus aureus** — some strains modulate LL-37 for host colonization These evolutionary adaptations are a reminder that LL-37 is not universally antimicrobial — outcomes depend on the specific organism. **Cancer Considerations:** LL-37 has context-dependent effects on cancer. Users with active cancer or high cancer risk (strong family history, genetic predispositions) should avoid LL-37 outside oncology-supervised research contexts. **Pregnancy and Breastfeeding:** No adequate safety data. Endogenous LL-37 plays complex roles in pregnancy. Avoid exogenous LL-37 during pregnancy or breastfeeding. **Drug Reaction Considerations:** LL-37 can interact with serum proteins and may theoretically affect pharmacokinetics of highly protein-bound drugs. Limited data. **Who Should Exercise Particular Caution:** - Anyone with psoriasis, rosacea, lupus, or other chronic inflammatory skin/autoimmune conditions - Users with mast cell activation syndrome or severe allergies - Users with renal dysfunction - Users with active cancer - Users with chronic infections involving specific organisms (GAS, some S. aureus strains) that may paradoxically benefit from LL-37 - Pregnant or breastfeeding women - Users on immunosuppressive therapy **What Is NOT a Primary Concern with LL-37 at Typical Doses:** - Hepatotoxicity - Cardiovascular events - Neurotoxicity - Endocrine disruption - Direct cancer initiation (effects are context-dependent) - Dependence or withdrawal Overall, LL-37 has a higher side-effect risk than most peptides in common use, and careful user selection is more important for LL-37 than for compounds like Tα1, BPC-157, or TB-500. It is not a universally safe peptide and should not be used casually.

Contraindications

**Absolute contraindications:** - Active psoriasis or psoriatic arthritis - Active rosacea - Active systemic lupus erythematosus - Active severe autoimmune dermatosis - Known hypersensitivity to LL-37 or cathelicidin preparations - Pregnancy - Breastfeeding - Severe mast cell activation syndrome - Active malignancy without oncology supervision **Strong relative contraindications:** - Personal history of psoriasis or rosacea (risk of flare or new-onset disease) - Strong family history of psoriasis - Moderate-to-severe renal impairment - History of severe drug or peptide allergy - Concurrent immunosuppressive therapy for autoimmunity (discuss with prescriber) - Chronic systemic inflammatory conditions not well controlled - Age < 18 **Drug interactions:** - **Psoriasis biologics (anti-IL-17, anti-IL-23, anti-TNF) or systemic methotrexate for psoriasis:** Pharmacologically opposed — adding LL-37 in a psoriasis patient is counterproductive - **Systemic corticosteroids at high dose:** May neutralize LL-37 effects - **Cyclosporine, tacrolimus:** Complex interactions; discuss with specialist - **Certain antibiotics with known LL-37 synergy:** may produce potentiated effects (usually beneficial but monitor for adverse events) - **Drugs with narrow therapeutic index that are highly protein-bound:** LL-37 can compete for binding; monitor carefully - **Other antimicrobial peptides** (other cathelicidins, defensins): uncharacterized combinations **Stop using if:** - New appearance of red scaly plaques characteristic of psoriasis - New or worsened rosacea-like facial erythema - New signs of autoimmune skin disease - Persistent severe injection site reactions - Signs of allergic reaction (hives, facial swelling, breathing difficulty) - Unexplained elevation in creatinine or BUN - Any concerning persistent systemic symptoms - Pregnancy (confirmed or suspected) - New cancer diagnosis **Monitoring:** - **Baseline:** CBC with differential, complete metabolic panel (particularly creatinine, BUN), CRP, vitamin D, relevant infection markers - **During therapy (4-6 weeks):** repeat CBC, metabolic panel, inflammatory markers - **For longer protocols:** quarterly labs; annual if continued - **Skin exam:** at baseline, at 4-6 weeks, and whenever new skin symptoms arise - **Individual awareness:** patient/user should know to watch for specific warning signs (new plaque-like redness, facial inflammation, severe injection reactions) **Specific Situations Requiring Caution:** - Users with unexplained skin rashes or conditions should have dermatology evaluation before starting LL-37 - Users with chronic infection diagnoses should ensure the diagnosis is well-established rather than assumed; some chronic illnesses mimicking "chronic Lyme" or "mold illness" have other etiologies that LL-37 cannot help - Users on complex polypharmacy should review medication list with clinician for interaction potential - Users with known renal disease should have baseline and follow-up creatinine before extended protocols **What Is Generally Safe About LL-37 (To Avoid Over-Warning):** - Short-term use in appropriate populations with clear indication has reasonable safety - Topical use on wounds has been extensively tested with good tolerability - Use alongside conventional infection therapy is commonly done without incident - Many users benefit without significant adverse events — the warnings above target specific at-risk populations **Medical Supervision:** LL-37 benefits significantly from integrative clinician supervision because: 1. Appropriate indication selection is essential (and non-obvious for off-label use) 2. Side-effect monitoring (particularly for inflammatory skin conditions) benefits from clinical assessment 3. Complex chronic illness protocols using LL-37 are multi-component and individualized Solo LL-37 use for complex chronic illness is not recommended. Users should work with Lyme-literate, functional medicine, or integrative medicine clinicians.

Check interactions with the Interaction Checker →

Additional Notes

Standard dose ranges:

Trial dose: 100-200 μg subcutaneous
Typical therapeutic: 250-500 μg subcutaneous per dose
Frequency: daily to 3x weekly
Upper common dose: 750 μg per injection
Not typically exceeded: 1 mg per injection (safety data limited above this)

Reconstitution specifics:

5 mg vial + 2 mL BAC water = 2.5 mg/mL. On insulin syringe: 1 unit = 25 μg; 10 units = 250 μg; 20 units = 500 μg.
5 mg vial + 1 mL BAC water = 5 mg/mL. On insulin syringe: 1 unit = 50 μg; 5 units = 250 μg; 10 units = 500 μg.

Storage:

Lyophilized LL-37: refrigerate or freeze; stable 12+ months sealed
Reconstituted LL-37: refrigerate at 2-8°C; stable 3-4 weeks
Do not freeze reconstituted solution
Protect from light
Discard if cloudy or particulate

Injection Technique:

Subcutaneous; 29-31G x 5/16" insulin needle
Abdomen, flanks, outer thighs rotation
Inject SLOWLY over 3-5 seconds — faster injection increases local irritation
Apply gentle pressure with clean gauze after withdrawal
Rotate sites aggressively to minimize cumulative local reactions

Timing:

Morning dosing preferred — allows monitoring for reaction during the day rather than during sleep
Take note of food, exercise, stress relationships with any reaction pattern
Consistent schedule matters less than with peptides that have specific circadian goals

Common Dosing Mistakes:

Starting at standard dose without tolerance test — can produce significant injection reactions or mask contraindications
Continuing despite new skin findings — stop and evaluate for autoimmune/inflammatory dermatosis
Using for vague wellness indications — LL-37 is not a general-purpose peptide; should be used for specific clinical reasons
Injecting too quickly — amplifies local reaction
Combining with multiple other peptides on first introduction — confounds adverse-event attribution
Skipping vitamin D optimization — endogenous LL-37 support is the first intervention
Using as monotherapy for serious infection — combine with appropriate primary therapy
Ignoring injection site reactions that persist beyond 48 hours — these warrant attention

Special Populations:

Elderly: standard or slightly reduced doses; renal function monitoring more important
Renal impairment: consider dose reduction; monitor creatinine
Hepatic impairment: theoretical concern for protein binding changes; monitor clinically
Pregnancy: avoid
Breastfeeding: avoid
Users with psoriasis, rosacea, lupus: avoid except under specialist supervision with specific rationale

Product Quality Considerations:

LL-37 synthesis requires careful quality control — the 37-amino-acid length and high cationic charge make the peptide more difficult to synthesize cleanly than shorter peptides. Poor-quality LL-37:

May have reduced antimicrobial activity
May have increased inflammatory potential due to truncated fragments
May have higher endotoxin contamination

Use vendors with published HPLC certificates showing >95% purity and low endotoxin levels. This matters more for LL-37 than for most peptides.

Upper Limit Considerations:

Doses above 1 mg per injection are not supported by evidence and may increase side-effect risk disproportionately. Cumulative daily doses above 1.5 mg should not be exceeded without specialist guidance.

Where to Buy LL-37

Compare 1 listing across 1 vendor — from $45.00

Frequently Asked Questions

What is the recommended LL-37 dosage?

Dosage for LL-37 varies by protocol. Consult a qualified healthcare provider.

How often should I take LL-37?

Administration frequency depends on the specific protocol. Consult current research literature.

Does LL-37 need to be cycled?

Cycling requirements depend on the protocol. Follow established research guidelines.

What are LL-37 side effects?

Where can I buy LL-37?

Compare 1 listings from 1 vendor on our price comparison page — starting from $45.00.

LL-37 Full Profile

Research data, mechanisms, and pricing

Interaction Checker

Check drug & compound interactions

Related Dosage Guides

All Guides

Thymosin Alpha-1 (TA1)

Immune & Inflammation · Dosage Guide

Free 2026 Peptide Cheat Sheet — 50 pages, PDF

Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.

Download Free